[The ability of low-molecular heparin (Fraxiparin) to overcome the action of exogenous coagulases--a fundamental difference from nonfractionated heparin].
A new previously unknown activity of the low molecular-weight heparin Fraxiparin (Sanofi) has been discovered. This is its ability to reduce the plasma clotting action of snake venom coagulases at final concentration of more than 12.5 anti-Xa U/ml, while the unfractionated heparin does not possess this property. The experiments demonstrated that Fraxiparin the action of Echis carinatus prothrombin-activating venom to a greater degree and Agkistrodon halys halys thrombin-like coagulase to a lesser degree. Unlike the unfractionated heparin, Fraxiparan also prevents the death of white rats from acute toxic hemocoagulant shock caused by the intravenous injection of DL100 Echis carinatus venom.
Barkagan
Z S
ZS
Tsyvkina
L P
LP
Koltakova
S I
SI
D017836:Agkistrodon; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D003030:Coagulase / Q000037:antagonists & inhibitors*; D003435:Crotalid Venoms / Q000201:enzymology / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D017762:Nadroparin / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D012769:Shock / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control; D014757:Viper Venoms / Q000201:enzymology / Q000633:toxicity
D003030:Coagulase; D003435:Crotalid Venoms; D017762:Nadroparin; D014757:Viper Venoms; D006493:Heparin
Sposobnost' nizkomolekuliarnogo geparina (fraksiparina) preodolevat' deĭstvie ékzogennykh koagulaz--fundamental'noe otlichie ot nefraktsionirovannogo geparina.